CTKB Stock Overview
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CTKB from our risk checks.
Cytek Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.82 |
| 52 Week High | US$7.63 |
| 52 Week Low | US$3.27 |
| Beta | 1.41 |
| 1 Month Change | -6.83% |
| 3 Month Change | -33.45% |
| 1 Year Change | -32.15% |
| 3 Year Change | -60.41% |
| 5 Year Change | n/a |
| Change since IPO | -79.64% |
Recent News & Updates
Recent updates
Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt?
Apr 16
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 13Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
Jan 09Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Nov 07Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Shareholder Returns
| CTKB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.7% | 1.6% | 2.3% |
| 1Y | -32.1% | -27.0% | 5.9% |
Return vs Industry: CTKB underperformed the US Life Sciences industry which returned -27% over the past year.
Return vs Market: CTKB underperformed the US Market which returned 5.9% over the past year.
Price Volatility
| CTKB volatility | |
|---|---|
| CTKB Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CTKB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CTKB's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 648 | Wenbin Jiang | cytekbio.com |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
Cytek Biosciences, Inc. Fundamentals Summary
| CTKB fundamental statistics | |
|---|---|
| Market cap | US$482.93m |
| Earnings (TTM) | -US$6.02m |
| Revenue (TTM) | US$200.45m |
2.4x
P/S Ratio-81.3x
P/E RatioIs CTKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTKB income statement (TTM) | |
|---|---|
| Revenue | US$200.45m |
| Cost of Revenue | US$89.35m |
| Gross Profit | US$111.11m |
| Other Expenses | US$117.13m |
| Earnings | -US$6.02m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 55.43% |
| Net Profit Margin | -3.00% |
| Debt/Equity Ratio | 1.4% |
How did CTKB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/24 22:01 |
| End of Day Share Price | 2025/04/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytek Biosciences, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Tejas Savant | Morgan Stanley |